ArticleBritish journal of cancer2017
Impact of body mass index on ovarian cancer survival varies by stage.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer genomics & proteomicsTrial
- The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Global Patterns and Temporal Trends in Ovarian and Uterine Cancer Mortality Attributable to High Body-Mass Index, 1990-2023.Cancers · 2026Article
- Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.Journal of ovarian research · 2025Article
- The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021.BMC public health · 2025Article
- The role of diet, obesity and body composition in epithelial ovarian cancer development and progression: Mechanisms and therapeutic implications.Gynecologic oncology reports · 2025Review
- Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer.Nutrients · 2025Article
- Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study.Frontiers in nutrition · 2025Article
- Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.Archives of gynecology and obstetrics · 2024Article
- Impact of Obesity and Lysosomal Dysfunction on Chemoresistance in Ovarian Cancer.Biomedicines · 2024Review
- Deciphering the Therapeutic Applications of Nanomedicine in Ovarian Cancer Therapy: An Overview.Current drug delivery · 2024Review
- Who is Focusing on Women's Health: A Bibliometric Analysis of Global Research Trends on Overweight in Female Patients with Gynecologic or Breast Cancer.International journal of women's health · 2024Article
- Awareness of ovarian cancer symptoms and risk factors in a young ethnically diverse British population.Cancer medicine · 2023Article
- The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer.Health science reports · 2022Article
- Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma.Nutrients · 2022Article
- Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.Cancers · 2022Review
- Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia.Saudi medical journal · 2022Article
- Ovarian cancer in Lebanese women: a 12-year comparative epidemiological study and trend analysis.Ecancermedicalscience · 2022Article
- Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer.Translational cancer research · 2019Article
- hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundResearch on the effect of body mass index (BMI) on ovarian cancer survival is inconsistent, but previous studies did not consider the possible impact of ascites, bowel obstruction, or cachexia, which commonly occur in late-stage disease.
methodsWe evaluated the association of BMI, before and around the time of diagnosis, with overall and disease-specific survival in a cohort study of primary invasive epithelial ovarian cancers diagnosed from 2000 to 2013 in Kaiser Permanente Northern California (KPNC) (n=1184). Deaths were identified through December 2014, with a median follow-up of 37 months. Proportional hazards regression was used to estimate overall and ovarian cancer-specific mortality, accounting for prognostic variables including age at diagnosis, race, stage, grade, histology, comorbidities, treatment, post-treatment CA125 levels, ascites, and bowel obstruction.
resultsThere was no evidence of an association between BMI and overall or ovarian cancer-specific survival. However, we found strong effect modification by stage (P
conclusionsAssociations of obesity with ovarian cancer survival may differ by stage, with decreased survival among those with localised disease and increased survival among those with late-stage disease. Stage-specific effects of obesity on survival suggest a tailored approach to improve prognosis may be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.